Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advancing cancer biotherapy with proteomics.

David F Stroncek1, Christine Burns, Brian M Martin

  • 1Immunogenetics Section, Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892-1148, USA. dstroncek@cc.nih.gov

Journal of Immunotherapy (Hagerstown, Md. : 1997)
|April 20, 2005
PubMed
Summary

Proteomics is crucial for cancer biotherapy, aiding in biomarker discovery and understanding treatment mechanisms. Advanced proteomic technologies help assess treatment effectiveness and toxicity, paving the way for personalized cancer care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood.

Journal of translational medicine·2026
Same author

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

Journal for immunotherapy of cancer·2026
Same author

Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse.

Cell·2026
Same author

Bringing in vivo CAR to the clinic: Promise, pitfalls, and questions to ask.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.

British journal of haematology·2026
Same author

Alpha-gal sensitization and allergic blood transfusion reactions: a scoping review.

Journal of translational medicine·2026

Area of Science:

  • Biochemistry
  • Oncology
  • Biotechnology

Background:

  • Proteomics is vital for advancing cancer biotherapy.
  • High-throughput platforms enable protein analysis from minimal samples.
  • Biomarker discovery is a key application of modern proteomics.

Purpose of the Study:

  • To review recent advances in proteomics for cancer biotherapy.
  • To explore the application of proteomics in assessing immunotherapy.
  • To examine the role of proteomics in evaluating high-dose IL-2 therapy.

Main Methods:

  • Review of recent scientific literature on proteomics in cancer.
  • Analysis of high-throughput proteomic platforms.
  • Case studies on immunotherapy and IL-2 cancer therapy.

Related Experiment Videos

Main Results:

  • Proteomics is essential for understanding complex biological processes in cancer therapy.
  • Proteomic technologies are effective in assessing treatment efficacy and toxicity.
  • Recent advances enhance the potential of proteomics for biomarker and predictor discovery.

Conclusions:

  • Proteomics is increasingly valuable for assessing cancer biotherapies and elucidating their mechanisms.
  • High-throughput proteomic tools show significant promise for identifying biomarkers of disease and treatment response.